Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Febuxostat vs allopurinol for prevention of tumor lysis syndrome in hematologic malignancies
2012-000776-42Phase 3Completed
- Sponsor
- Menarini Group
- Start
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of febuxostat in tumor lysis syndrome (TLS) (2 arms), sponsored by Menarini Group. Primary endpoints: Serum uric acid level control at Day 8 and Preservation of renal function at Day 8. Started May 2012; status: completed.
02
Drugs
febuxostat
03
Conditions
tumor lysis syndrome (TLS)
Beyond the preview
Go deeper on 2012-000776-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000776-42.